Alexander Wiedenmann

USPTO Granted Patents = 22 (Patent Applications = 3)

CIPO Patents = 1 (Patent Applications = 8)

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 7.5

ph-index = 3

Forward Citations = 49(Granted Patents)

Location History:

Neufahrn, DE (2015 - 2017)
Neufahm bei Freising, DE (2020)
Herbrechtingen, DE (2018 - 2021)
Ulm, DE (2019 - 2022)

Company Filing History:

12 out of 36

Pieris Pharmaceuticals Gmbh

Daiichi Sankyo Company, Limited

patents

4. 1 out of 1

Pieris Australia Pty Ltd.

patent

5. 1 out of 832,680

Other

patents

Years Active: 2015-2022

Loading Chart...

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11345728 - Specific-binding polypeptides and uses thereof (2022-05-31),

2. 11034738 - Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2) (2021-06-15),

3. 11034737 - Proteins specific for calcitonin gene-related peptide (2021-06-15),

4. 10947284 - Fusion molecules (2021-03-16),

5. 10927156 - Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune response (2021-02-23),

6. 10927154 - Multi-specific polypeptide useful for localized tumor immunomodulation (2021-02-23),

7. 10787491 - Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) (2020-09-29),

8. 10774119 - Specific-binding polypeptides and uses thereof (2020-09-15),

9. 10703810 - Fusion polypeptides which bind vascular endothelial growth factor a (VEGF-A) and angiopoietin-2 (Ang-2) (2020-07-07),

10. 10526384 - Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof (2020-01-07),

11. 10526382 - Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereof (2020-01-07),

12. 10501510 - Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereof (2019-12-10),

13. 10400016 - Proteins specific for calcitonin gene-related peptide (2019-09-03),

14. 10329334 - Proteins specific for pyoverdine and pyochelin (2019-06-25),

15. 10316071 - Fusion molecules (2019-06-11),

Title: The Innovative Contributions of Alexander Wiedenmann

Introduction

Alexander Wiedenmann, located in Ulm, Germany, is a prominent inventor known for his significant contributions to the field of biotechnology. With an impressive portfolio of 22 patents, his work primarily focuses on therapeutic and diagnostic polypeptides that have applications in various medical fields.

Latest Patents

Among his latest innovations, Wiedenmann has developed specific-binding polypeptides that are directed against the targets of Swiss Prot Q16552 and Swiss Prot Q9NPF7. This invention encompasses novel polypeptides designed for both therapeutic and diagnostic purposes, alongside nucleic acid molecules that encode these polypeptides. Furthermore, the invention includes methods for generating such polypeptides and nucleic acid molecules, as well as compositions composed of these polypeptides, highlighting their potential therapeutic applications.

Another recent patent from Wiedenmann involves proteins specific for calcitonin gene-related peptide (CGRP). This disclosure offers hNGAL muteins capable of binding CGRP, which have important applications in the pharmaceutical realm, particularly for the treatment of migraines. The patent also outlines methods for creating these muteins and discusses the compositions and combinations that can include them, further underscoring their diagnostic and therapeutic potential.

Career Highlights

Wiedenmann's career has involved significant roles at leading companies such as Pieris Pharmaceuticals GmbH and Sanofi. His work at these organizations reflects his dedication to advancing medical technologies and therapeutic strategies.

Collaborations

Throughout his career, Wiedenmann has had the opportunity to collaborate with notable professionals in the industry, including Andrea Allersdorfer and Marlon Hinner. These collaborations have likely contributed to the breadth and depth of his innovative work.

Conclusion

Alexander Wiedenmann stands out as a key figure in the field of biotechnology, with numerous patents that pave the way for exciting advancements in therapeutic and diagnostic applications. His contributions not only reflect his personal expertise but also highlight the value of collaboration within the innovative landscape of biomedicine.

This text is generated by artificial intelligence and may not be accurate.